Literature DB >> 19891660

Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas.

Eri Hiroki1, Jun-Ichi Akahira, Fumihiko Suzuki, Satoru Nagase, Kiyoshi Ito, Takashi Suzuki, Hironobu Sasano, Nobuo Yaegashi.   

Abstract

This study aimed to determine the expression profiles of microRNAs (miRNAs) in endometrial serous adenocarcinoma and to examine the association between miRNA expression and clinical outcomes. Twenty-one patients diagnosed with endometrial serous adenocarcinoma between January 2001 and December 2006 were enrolled. miRNA expression profiles were examined using miRNA microarray and qRT-PCR. miRNA expression levels were correlated with clinicopathological variables and survival rates. A total of 120 miRNAs were differentially expressed in endometrial serous adenocarcinoma compared to normal endometria. Of these, 54 miRNAs were down-regulated (>2-fold), including miR-101, miR-10b*, miR-152, and miR-29b, and the remainder were up-regulated (>2-fold), including miR-200a, miR-200b, and miR-205. Decreased expression of miR-10b*, miR-29b, and miR-455-5p was correlated with vascular invasion (P = 0.048, P = 0.013, and P = 0.032, respectively). Univariate analysis revealed that lower expression of miR-101, miR-10b*, miR-139-5p, miR-152, miR-29b, and miR-455-5p was significantly correlated with poor overall survival (P < 0.05), and reduced expression of miR-152, miR-29b, and miR-455-5p was significantly correlated with poor disease-free survival (P < 0.05). Multivariate analysis demonstrated that decreased expression of miR-152 (P = 0.021) was a statistically independent risk factor for overall survival, and decreased expression levels of miR-101 (P = 0.016) and miR-152 (P = 0.010) were statistically independent risk factors for disease-free survival. In addition, transfection of miR-101 or miR-152 precursors into an endometrial serous carcinoma cell line inhibited cell growth (P < 0.0001 and P = 0.01, respectively). Moreover, strong positive immunoreactivity of cyclooxygenase-2 (COX-2) was significantly correlated with down-regulation of miR-101 (P = 0.035). These findings suggest that the dysregulation of miRNAs is associated with the poor prognosis in endometrial serous adenocarcinoma patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19891660     DOI: 10.1111/j.1349-7006.2009.01385.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  95 in total

1.  MicroRNA screening identifies circulating microRNAs as potential biomarkers for osteosarcoma.

Authors:  Hui Li; Kun Zhang; Li-Hong Liu; Yurong Ouyang; Hong-Bin Guo; Hanchong Zhang; Jie Bu; Tao Xiao
Journal:  Oncol Lett       Date:  2015-06-16       Impact factor: 2.967

2.  miR-200a/miR-141 and miR-205 upregulation might be associated with hormone receptor status and prognosis in endometrial carcinomas.

Authors:  Ying Dong; Jing-Wen Si; Wen-Ting Li; Li Liang; Jian Zhao; Mei Zhou; Dong Li; Ting Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  MicroRNA and endometrial cancer: Roles of small RNAs in human tumors and clinical applications (Review).

Authors:  Megumi Yanokura; Kouji Banno; Yusuke Kobayashi; Iori Kisu; Arisa Ueki; Asuka Ono; Kennta Masuda; Hiroyuki Nomura; Akira Hirasawa; Nobuyuki Susumu; Daisuke Aoki
Journal:  Oncol Lett       Date:  2010-09-22       Impact factor: 2.967

Review 4.  Minireview: The roles of small RNA pathways in reproductive medicine.

Authors:  Shannon M Hawkins; Gregory M Buchold; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2011-05-05

5.  Tumor-specific silencing of COPZ2 gene encoding coatomer protein complex subunit ζ 2 renders tumor cells dependent on its paralogous gene COPZ1.

Authors:  Michael Shtutman; Mirza Baig; Elina Levina; Gregory Hurteau; Chang-Uk Lim; Eugenia Broude; Mikhail Nikiforov; Timothy T Harkins; C Steven Carmack; Ye Ding; Felix Wieland; Ralph Buttyan; Igor B Roninson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-11       Impact factor: 11.205

6.  MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease.

Authors:  Kah Hoong Chang; Nicola Miller; Elrasheid A H Kheirelseid; Christophe Lemetre; Graham R Ball; Myles J Smith; Mark Regan; Oliver J McAnena; Michael J Kerin
Journal:  Int J Colorectal Dis       Date:  2011-07-08       Impact factor: 2.571

7.  Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study.

Authors:  Luděk Záveský; Eva Jandáková; Radovan Turyna; Lucie Langmeierová; Vít Weinberger; Lenka Záveská Drábková; Martina Hůlková; Aleš Hořínek; Daniela Dušková; Jaroslav Feyereisl; Luboš Minář; Milada Kohoutová
Journal:  Pathol Oncol Res       Date:  2015-04-01       Impact factor: 3.201

8.  Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma.

Authors:  Yin Xie; Rong-Rong Wei; Guo-Liang Huang; Mei-Yin Zhang; Yun-Fei Yuan; Hui-Yun Wang
Journal:  Med Oncol       Date:  2014-01-25       Impact factor: 3.064

9.  miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy.

Authors:  Elrasheid A H Kheirelseid; Nicola Miller; Kah Hoong Chang; Catherine Curran; Emer Hennessey; Margaret Sheehan; John Newell; Christophe Lemetre; Graham Balls; Michael J Kerin
Journal:  Int J Colorectal Dis       Date:  2012-08-18       Impact factor: 2.571

Review 10.  RNAi-based strategies for cyclooxygenase-2 inhibition in cancer.

Authors:  Antonio Strillacci; Cristiana Griffoni; Maria Chiara Valerii; Giorgia Lazzarini; Vittorio Tomasi; Enzo Spisni
Journal:  J Biomed Biotechnol       Date:  2010-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.